Targeting <i>APOC3</i> with Olezarsen in Moderate Hypertriglyceridemia

Among patients with moderate hypertriglyceridemia and elevated cardiovascular risk, treatment with olezarsen resulted in significantly greater reduction in triglyceride levels at 6 months than placebo. (Funded by Ionis Pharmaceuticals; ESSENCE-TIMI 73b ClinicalTrials.gov number, NCT05610280.).

Authors

Institutions

Publication Details

Journal
New England Journal of Medicine
Published
2025-08-30
DOI
https://doi.org/10.1056/nejmoa2507227
Citations
32
Primary Topic
Lipid metabolism and disorders
Type
article
Field-Weighted Citation Impact
44.42

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia

Thomas A Prohaska, Erica L. Goodrich, Marc S. Sabatine, Robert P. Giugliano et al.
32 citations
New England Journal of Medicine
Lipid metabolism and disorders
44.42
article

Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia

Thomas A Prohaska, Erica L. Goodrich, Marc S. Sabatine, Robert P. Giugliano, Maciej Banach, Brian A. Bergmark, Michael T. Lu, Filipe A. Moura, S. M. Zhang, Veronica J. Alexander, André Zimerman, Sabina A. Murphy, Sotirios Tsimikas, Nicholas Marston, Julia Weinland, Dan Li, Yu Mi Kang
article en
32 citations

Abstract

Among patients with moderate hypertriglyceridemia and elevated cardiovascular risk, treatment with olezarsen resulted in significantly greater reduction in triglyceride levels at 6 months than placebo. (Funded by Ionis Pharmaceuticals; ESSENCE-TIMI 73b ClinicalTrials.gov number, NCT05610280.).

New England Journal of MedicineVol. 393(13)
Brigham and Women's Hospital (US), Harvard University (US), Ionis Pharmaceuticals (United States) (US), Yale University (US), University of California San Diego (US), Hospital Moinhos de Vento (BR), VA Connecticut Healthcare System (US), Massachusetts General Hospital (US), Medical University of Lodz (PL), Amsterdam University Medical Centers (NL), Thrombolysis in Myocardial Infarction Study Group (US)
Ionis Pharmaceuticals
Openalex Percentile: Top 0%
Lipid metabolism and disorders
44.42
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.